FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
Doctors Can Now Prescribe Ozempic to Reduce Kidney Disease Risks in Diabetes Patients
Fact checked by Jillian Dara The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease.
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD).
Ozempic Receives New Indications in Chronic Kidney Disease
Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.
FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes
Doctors already use Ozempic to manage type 2 diabetes and reduce the risk of heart disease in patients with diabetes. This move, as reported by The Times, was based on research sh
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo’s Ozempic Gains US Nod for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
FDA clears use of Ozempic to protect kidney health
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, which hasn’t yet proven it can improve outcomes in kidney disease.
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
An Ozempic Expert Explains What You Need to Know Before Taking GLP-1 Drugs
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
Ozempic May Protect Against Alzheimer’s
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...
Cycling Weekly on MSN1d
Lighter but weaker? The hidden costs of Ozempic and weight-loss drugs for endurance athletes
Ozempic and other semaglutide medications have skyrocketed in popularity as weight-loss aids, with prescriptions surging by ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
Ozempic May Reduce Bone Density; Know Other Possible Side Effects
A healthy diet with regular exercise can help with sustainable weight loss. However, the use of Ozempic may contribute to ...